Compare SPCB & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | CTSO |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | SPCB | CTSO |
|---|---|---|
| Price | $8.48 | $0.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $5.38 |
| AVG Volume (30 Days) | 50.7K | ★ 139.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | $26,739,000.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $7.26 |
| Revenue Next Year | $27.13 | $9.78 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $5.06 | $0.60 |
| 52 Week High | $18.95 | $1.61 |
| Indicator | SPCB | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 49.64 |
| Support Level | $8.98 | $0.62 |
| Resistance Level | $9.47 | $0.68 |
| Average True Range (ATR) | 0.49 | 0.05 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 11.11 | 48.48 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.